Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ic cases » 19 cases (Expand Search), _ cases (Expand Search), 3 cases (Expand Search)
c2 cases » 152 cases (Expand Search), chd cases (Expand Search), 123 cases (Expand Search)
i large » _ large (Expand Search), a large (Expand Search), via large (Expand Search)
b large » _ large (Expand Search), a large (Expand Search), _ larger (Expand Search)
Showing 141 - 160 results of 12,363 for search '(((( i large decrease ) OR ( b large decrease ))) OR ( ((ic cases) OR (c2 cases)) increased ))*', query time: 0.66s Refine Results
  1. 141
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 142
    Table_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.xls

    Table_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.xls by Chengliang Yin (7545749)

    Published 2020
    “…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
    Save to List
    Saved in:
  3. 143
    Image_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.TIF

    Image_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.TIF by Chengliang Yin (7545749)

    Published 2020
    “…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
    Save to List
    Saved in:
  4. 144
    Image_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.TIF

    Image_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.TIF by Chengliang Yin (7545749)

    Published 2020
    “…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
    Save to List
    Saved in:
  5. 145
    Table_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.xls

    Table_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.xls by Chengliang Yin (7545749)

    Published 2020
    “…However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.</p>Methods<p>We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). …”
    Save to List
    Saved in:
  6. 146
    Excessive LF4A kinase activity shortens cilia and decreases IFT.

    Excessive LF4A kinase activity shortens cilia and decreases IFT. by Yu-Yang Jiang (7036916)

    Published 2019
    Save to List
    Saved in:
  7. 147
    Incidence rate ratio of hospitalizations between IC/BPS and non-IC/BPS individuals.

    Incidence rate ratio of hospitalizations between IC/BPS and non-IC/BPS individuals. by Kun-Lin Hsieh (11401919)

    Published 2021
    Save to List
    Saved in:
  8. 148
    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.4), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 <sup>a</sup> indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  9. 149
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 <sup>a</sup> indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  10. 150
    Z-stack showing <i>N</i>. <i>bombycis</i> adhering to the surface of the ovariole at the vitellogenesis stage on the fifth day of pupation.

    Z-stack showing <i>N</i>. <i>bombycis</i> adhering to the surface of the ovariole at the vitellogenesis stage on the fifth day of pupation. by Chunxia Wang (766713)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 151
    Z-stack showing <i>N</i>. <i>bombycis</i> infection in follicular cells at the vitellogenesis stage on the fifth day of pupation.

    Z-stack showing <i>N</i>. <i>bombycis</i> infection in follicular cells at the vitellogenesis stage on the fifth day of pupation. by Chunxia Wang (766713)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 152
    Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx

    Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx by Dewan Zhao (21547445)

    Published 2025
    “…Introduction<p>Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. …”
    Save to List
    Saved in:
  13. 153
    Z-stack showing <i>N</i>. <i>bombycis</i> infection in the nurse cells and oocytes at the vitellogenesis stage on the fifth day of pupation.

    Z-stack showing <i>N</i>. <i>bombycis</i> infection in the nurse cells and oocytes at the vitellogenesis stage on the fifth day of pupation. by Chunxia Wang (766713)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 154
    Z-stack showing <i>N</i>. <i>bombycis</i> adhering to the surface of the ovariole aat the previtellogenesis stage on the fifth day of pupation.

    Z-stack showing <i>N</i>. <i>bombycis</i> adhering to the surface of the ovariole aat the previtellogenesis stage on the fifth day of pupation. by Chunxia Wang (766713)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 155
    Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX

    Table4_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
    Save to List
    Saved in:
  16. 156
    Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX

    Table3_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
    Save to List
    Saved in:
  17. 157
    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX

    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
    Save to List
    Saved in:
  18. 158
    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX

    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
    Save to List
    Saved in:
  19. 159
    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX

    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
    Save to List
    Saved in:
  20. 160
    Results of SD-TOPSIS application ‐ combinations B1-B5.

    Results of SD-TOPSIS application ‐ combinations B1-B5. by Roman Vavrek (13200141)

    Published 2024
    Save to List
    Saved in:

Search Tools: